Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
IPO Year: 2015
Exchange: NYSE
Website: glaukos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2024 | $132.00 | Buy → Neutral | Citigroup |
| 5/6/2024 | $84.00 → $125.00 | Hold → Buy | Jefferies |
| 12/21/2023 | $66.00 → $91.00 | Neutral → Overweight | JP Morgan |
| 12/4/2023 | $65.00 | Equal-Weight | Morgan Stanley |
| 11/28/2023 | $88.00 | Buy | Truist |
| 11/8/2023 | $75.00 → $83.00 | Equal Weight → Overweight | Wells Fargo |
| 6/7/2023 | $55.00 → $80.00 | Neutral → Overweight | Piper Sandler |
| 12/22/2022 | $48.00 | Neutral | Mizuho |
| 12/19/2022 | $48.00 → $42.00 | Underweight → Neutral | JP Morgan |
| 12/12/2022 | $57.00 | Neutral → Buy | Citigroup |
Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form
Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K/A - GLAUKOS Corp (0001192448) (Filer)
10-Q - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, November 20, 2024, at 10:00 a.m. ET in Nashville, TN BTIG Ophthalmology Day on Monday, December 2, 2024, at 4:40 p.m. ET (Virtual) Piper Sandler Annual Healthcare Conference on Wednesday, December 4, 2024, at 1:00 p.m. ET in New York City
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2024. Key highlights for the third quarter of 2024 include: Record net sales of $96.7 million increased 24% year-over-year. Glaucoma record net sales of $76.0 million increased 30% year-over-year. Corneal Health net sales of $20.6 million increased 5% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately 82%. Raised 2024 net sales guidance to $377 million to $379 million, compared
Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 Data Suggest Epioxa Has the Potential to Provide the Ophthalmic Community and Patients with the First FDA-Approved, Non-Invasive Drug Therapy Alternative for Keratoconus Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the second Phase 3 confirmatory pivotal trial for Epioxa™ (Epi-on), its next-g
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 4, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (In
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 12:45 p.m. ET in Boston, MA Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 12:20 p.m. ET in New York City, NY A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2024. Key highlights include: Record net sales of $95.7 million in Q2 2024 increased 19% year-over-year on a reported basis and 20% year-over-year on a constant currency basis. Glaucoma record net sales of $75.9 million in Q2 2024 increased 23% year-over-year. Corneal Health net sales of $19.8 million in Q2 2024 increased 7% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 82%
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 31, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (In
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its 2.75% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million principal amount of Existing Convertible Notes for aggregate consideration consisting of a number of shares of the company's common stock, par value $0.001 per share (the "Common Stock"), to be determined over an averaging period commencing o
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024, at 1:40 p.m. ET in Chicago, IL Truist MedTech Conference on Tuesday, June 18, 2024, at 12:45 p.m. ET in Boston, MA A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. Corneal Health net sales of $18.4 million in Q1 2024 increased 4% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 83% in Q1 2024. Raised 2024 net sales guidance to $357 to $365 million, c
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2024. Key highlights for the third quarter of 2024 include: Record net sales of $96.7 million increased 24% year-over-year. Glaucoma record net sales of $76.0 million increased 30% year-over-year. Corneal Health net sales of $20.6 million increased 5% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately 82%. Raised 2024 net sales guidance to $377 million to $379 million, compared
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 4, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (In
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2024. Key highlights include: Record net sales of $95.7 million in Q2 2024 increased 19% year-over-year on a reported basis and 20% year-over-year on a constant currency basis. Glaucoma record net sales of $75.9 million in Q2 2024 increased 23% year-over-year. Corneal Health net sales of $19.8 million in Q2 2024 increased 7% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 82%
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 31, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (In
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. Corneal Health net sales of $18.4 million in Q1 2024 increased 4% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 83% in Q1 2024. Raised 2024 net sales guidance to $357 to $365 million, c
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (Interna
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year on a constant currency basis. Glaucoma net sales of $60.6 million in Q4 2023 increased 15% year-over-year. Corneal Health net sales of $21.8 million in Q4 2023 increased 19% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approx
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 21, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need FDA approval based on robust Phase 3 clinical program consisting of two pivotal studies that randomized 1,150 subjects across 89 clinical sites Glaukos to host a conference call on December 14, 2023, at 8:30 a.m. ET / 5:30 a.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases,
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. Glaucoma net sales of $58.3 million in Q3 2023 increased 9% year-over-year. Corneal Health net sales of $19.7 million in Q3 2023 increased 12% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 83% in Q3 2023.
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis
Citigroup downgraded Glaukos from Buy to Neutral and set a new price target of $132.00
Jefferies upgraded Glaukos from Hold to Buy and set a new price target of $125.00 from $84.00 previously
JP Morgan upgraded Glaukos from Neutral to Overweight and set a new price target of $91.00 from $66.00 previously
Morgan Stanley initiated coverage of Glaukos with a rating of Equal-Weight and set a new price target of $65.00
Truist initiated coverage of Glaukos with a rating of Buy and set a new price target of $88.00
Wells Fargo upgraded Glaukos from Equal Weight to Overweight and set a new price target of $83.00 from $75.00 previously
Piper Sandler upgraded Glaukos from Neutral to Overweight and set a new price target of $80.00 from $55.00 previously
Mizuho initiated coverage of Glaukos with a rating of Neutral and set a new price target of $48.00
JP Morgan upgraded Glaukos from Underweight to Neutral and set a new price target of $42.00 from $48.00 previously
Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $57.00
Truist Securities analyst Samuel Brodovsky maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $125 to $141.
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $112 to $131.
Morgan Stanley analyst Patrick Wood maintains Glaukos (NYSE:GKOS) with a Equal-Weight and raises the price target from $100 to $120.
During the last three months, 10 analysts shared their evaluations of Glaukos (NYSE:GKOS), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 4 2 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $120.7, a high estimate of $132.00, and a low estimate of $110.00. Surpassing the previous average price target
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Redburn Atlantic analyst Agnieszka Pustula downgraded the rating for Spotify Technology S.A. (NYSE:SPOT) from Neutral to Sell and announced a price target of $230. Spotify shares fell 0.7% to close at $311.55 on Tuesday. See how other analysts view this stock. B of A Securities analyst Jason Kupferberg downgraded Visa Inc. (NYSE:V) from Buy to Neutral, while cutting the price target from $305 to $297. Visa shares fell 0.4% to close at $265.44 on Tuesday. See how other analysts view thi
Citigroup analyst Joanne Wuensch downgrades Glaukos (NYSE:GKOS) from Buy to Neutral and raises the price target from $130 to $132.
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its 2.75% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million principal amount of Existing Convertible Notes for aggregate consideration consisting of a number of shares of the company's common stock, par value $0.001 per share (the "Common Stock"), to be determined over an averaging period commencing on
Stifel analyst Thomas Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $110 to $130.
Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price target from $110 to $120.
Glaukos (NYSE:GKOS) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 4 2 0 0 0 2M Ago 3 0 1 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $114.58, a high estimate of $130.00, an
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)